HepatologyNews.net

Hepatology Xagena

Six treatment options are available in 2015 for patients infected with HCV genotype 1, including two IFN-containing regimens and four IFN-free regimens. The combination of Sofosbuvir and Ribavirin s ...


All treatment-naïve and –experienced patients with compensated or decompensated chronic liver disease related to ( hepatitis C virus ) HCV, who are willing to be treated and who have no contra-indicat ...


Significant clinical variations exist among patients with hepatocellular carcinoma ( HCC ), the most common type of liver cancer, depending on the viral cause of the disease, hepatitis B virus ( HBV ) ...


Vitamin D receptors ( VDR ) bind calcitriol and modulate several physiological systems through genomic and nongenomic pathways. Calcitriol stimulates store-operated channels Ca influx by translocation ...


Interferon-based treatment is not suitable for many patients with hepatitis C virus ( HCV ) infection because of contraindications such as psychiatric illness, and a high burden of adverse events. L ...


Interferon-containing regimens for the treatment of hepatitis C virus ( HCV ) infection are associated with increased toxic effects in patients who also have cirrhosis. Researchers have evaluated ...


Glycerol phenylbutyrate ( Ravicti ) lowers ammonia by providing an alternate pathway to urea for waste nitrogen excretion in the form of phenylacetyl glutamine, which is excreted in urine. A rando ...


The first detailed results from pivotal phase III study, PEARL-III, were presented as part of the 21st Conference on Retroviruses and Opportunistic Infections ( CROI ). PEARL-III evaluated the effica ...


Forty percent of patients with autoimmune hepatitis ( AIH ) present with acute jaundice / hepatitis. Such patients, when treated promptly, are thought to have a good prognosis. The objective of a s ...


Entecavir ( Baraclude ) is effective and safe in patients with chronic hepatitis B in the short term, but its long term efficacy and safety has not been established. Researchers have evaluated HBV ...


High rates of sustained virologic response were observed among patients with hepatitis C virus ( HCV ) infection who received 12 weeks of treatment with the nucleotide polymerase inhibitor Sofosbuvir ...


The Interferon-free combination of the protease inhibitor ABT-450 with Ritonavir ( ABT-450/r ) and the NS5A inhibitor Ombitasvir ( also known as ABT-267 ) plus the nonnucleoside polymerase inhibitor D ...


In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor Sofosbuvir and the NS5A inhibitor Ledipasvir resulted in high rates of sustained virologic response a ...


Interferon-containing regimens for the treatment of hepatitis C virus ( HCV ) infection are associated with increased toxic effects in patients who also have cirrhosis. Researchers have evaluated th ...


In this phase 3 trial researchers have evaluated the efficacy and safety of the Interferon-free combination of ABT-450 with Ritonavir ( ABT-450/r ), Ombitasvir ( also known as ABT-267 ), Dasabuvir ( a ...


Effective treatment for hepatitis C virus ( HCV ) genotype 1 infection in patients who have not had a sustained virologic response to prior Interferon-based therapy represents an unmet medical need. ...


Results from a phase III study presented at the International Liver Congress 2014 have shown Obeticholic acid ( OCA ) given to patients suffering from primary biliary cirrhosis ( PBC ) who previously ...


The new Interferon-free, all-oral, three direct-acting-antiviral ( 3D ) treatment regimen in development by AbbVie has achieved very high rates of virological response in patients chronically infected ...


Results from RESTORE , a phase III, multicentre, single-arm, open-label study presented at the International Liver Congress 2014 showed that Simeprevir ( Olysio )150 mg once-daily for 12 weeks in comb ...


In a study involving treatment-naive and treatment-experienced patients of Egyptian ancestry with chronic genotype 4 HCV infection, Sofosbuvir ( Sovaldi ) plus Ribavirin was shown to provide a simple, ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati